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IMMUNOISOLATION PATCH SYSTEM FOR 
CELLULAR TRANSPLANTATION 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
The present invention claims priority to U.S. Provisional 
Patent Application No. 61/047,860, filed Apr. 25, 2008, 
which is incorporated herein by reference in its entirety. 
STATEMENT REGARDING 
FEDERALLY-SPONSORED RESEARCH 
This invention was made with government support under 
contract NAG 5-12429 awarded by NASA. The government 
has certain rights in the invention. 
FIELD OF THE INVENTION 
The present invention relates to an immunoisolation patch 
system, and particularly a patch system comprising multiple 
immunoisolation microcapsules, each encapsulating biologi-
cal material such as cells for transplantation. The present 
invention also relates to methods of using an immunoisola-
tion patch system for the prophylactic and therapeutic treat-
ment of disease in large animals and humans without the need 
for immunosuppression. 
BACKGROUND OF THE INVENTION 
Cellular transplantation has recently generated enthusiasm 
for treating a number of human diseases characterized by 
hormone or protein deficiencies, such as diabetes, Parkin-
son's disease, Huntington's disease, liver disease and others. 
However, a number of technical and logistical challenges 
have prevented cellular transplantation from working effec-
tively. In particular, transplanted cells must be protected from 
immune attack by the transplant recipient. This often requires 
potent immuno suppressive agents having considerable toxic-
ity that can expose the patient to a wide variety of serious side 
effects. While immuno suppressive agents increase the chance 
that the host will accept the cell therapy treatment, it has been 
well documented that immunosuppressive drugs can cause 
deleterious effects to the host. In particular, immunosuppres-
sive agents lower a subject's resistance to infection, make 
infections harder to treat, and increase the chance of uncon-
trolled bleeding. The drugs may also be harmful to the trans-
planted cells. 
An alternative approach is to enclose the transplanted cells 
within a semi-permeable membrane. In theory, the semi-
permeable membrane is designed to protect cells from 
immune attack while allowing for both the influx of mol-
ecules important for cell function and survival and the efflux 
of the desired cellular product, for example insulin. This 
immunoisolation approach has two major potentials: i) cell 
transplantation without the need for immunosuppressive 
drugs and their accompanying side effects, and ii) use of cells 
from a variety of sources such as autografts (host stem-cell 
derived), allografts (either primary cells or stem-cell 
derived), xenografts (porcine cells or others), or genetically 
engineered cells. 
Macro-immunoisolation systems including intravascular 
and diffusive devices (e.g., hollow fibers, tubular membranes, 
flat sandwich pouches, islet sheets, and islet patches) have 
been tested in diabetic rodents and dogs, and results indicate 
that many of these systems can function for periods of time. 
However, these designs have limited application, because 
implantation is highly invasive surgically, device failure is 
common, and the side effects of device failure are high. For 
example, a single breach in macro diffusion devices can cause 
massive islets death and system failure, and if the breach is 
5 sudden, a lethal dose of insulin can be released from the islets, 
causing death of the host. 
Micro-immunoisolation systems, although they overcome 
many of the problems associated with macro systems, have 
their own drawbacks. Certain microimmunoisolation sys- 
10 tems have been tested in large animal models, but many of 
those experiments were performed on spontaneous diabetic 
subjects or utilized immunosuppressive agents. Sun et al. 
"Normalization of diabetes in spontaneously diabetic cyno-
molgus monkeys by xenografts of microencapsulatod porcine 
15 islets without immunosuppressant" J. Clin. Invest. 98:1417-
22 (1996); Lanza et al. "Transplantation of islets using 
microencapsulation: studies in diabetic rodents and dogs" J. 
Mol. Med. 77(1):206-10 (1999); R. Calafiore "Transplanta-
tion of minimal volume microcapsules in diabetic high mam- 
20 malians"AnnNYAcad. Sci. 875:219-32 (1999); Hering et al. 
"Long term (>100 days) diabetes reversal in immunosup-
pressed nonhuman primate recipients of porcine islet xeno-
graphs" American J. Transplantation 4:160-61 (2004); and 
Soon-Shiong et al. "Insulin independence in a Type 1 diabetic 
25 patient after encapsulated islet transplantation" Lancet 343: 
950-951 (1994). Moreover, many of these experiments could 
not be reproduced to acceptable scientific standards. The lack 
of experimental control and consistency of those experiments 
has complicated scientific interpretation and limited their 
30 applicability. 
Prior micro-immunoisolation systems have involved the 
transplantation of encapsulated cells directly into the body 
cavity of the subject, for example by hypodermic injection or 
by creating a surgical opening in the body cavity and intro- 
35 ducing the encapsulated cells into the body cavity through the 
opening. Once inside the body cavity, the encapsulated cells 
could then migrate or diffuse in the body cavity, and may 
attach to undesirable locations, for example the outer wall of 
the liver or kidney, which could disrupt the function of those 
40 organ, leading to other medical concerns. Micro-immunoiso-
lation systems also suffer from the effects of gravitational 
sedimentation, which can lead to undesirable system migra-
tion and clumping of encapsulated cells within the body, 
which can cause a number of undesirable side effects and 
45 prevent effective functioning of the implant. 
Thus, the promise of immunoprotection of living cells to 
treat hormone-deficient diseases has not been realized. 
Accordingly, what is needed in the art is a reproducible and 
effective cell therapy treatment that can be used in large 
50 mammals including humans without the use of immunosup-
pressive drugs. 
SUMMARY OF THE INVENTION 
55 	 The present invention relates to immunoisolation patches 
for use in cellular transplantation therapy of a disorder, com-
prising a plurality of multi-membrane microcapsules which 
encapsulate cellular material and a biocompatible support 
matrix in which the plurality of multi-membrane microcap- 
60 sules are distributed, wherein at least some of said plurality of 
multi-membrane microcapsules comprise at least two mem-
brane layers: an inner membrane biocompatible with the 
encapsulated cellular material, and an outer membrane which 
provides chemical stability to the immunoisolation patch sys- 
65 tem. The disorder can be an endocrine disorder such as dia-
betes orhypothyroidism, a neurological disorder, or any other 
disorder able to be treated with cell therapy. Methods of 
US 8,673,294 B2 
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treating (prophylactically or therapeutically) a mammal with 
the immunoisolation patches are also disclosed. Additional 
advantages and features of the present invention will be 
apparent from the following detailed description, drawings 
and examples, which illustrate preferred embodiments of the 
invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG.1 illustrates an immunoisolation patch of an embodi-
ment of the present invention. 
FIG. 2 depicts a multi-layer microcapsule, which encapsu-
lates biological material, of an embodiment of the present 
invention. 
FIG. 3 illustrates microcapsule mechanical stability. The 
chart illustrates the mechanical strength of capsules of two 
different polymer concentrations by plotting the rupture load 
versus the microcapsule membrane thickness and size. 
FIG. 4 shows the microcapsule stability. The chart illus-
trates the mechanical strength of two capsules as a function of 
time with different chemical compositions and membrane 
thickness. 
FIG. 5 depicts the permeability of the microcapsule mem-
brane. The chart illustrates normalized retention time as a 
function of pore size distribution of microcapsule membrane. 
FIG. 6 depicts the perfusion of encapsulated islets. The 
secretion level of insulin-releasing islets was assessed in a 
cell perfusion system. Free islets (not encapsulated), islets 
encapsulated in a single-membrane system (encapsulated 
islets), and islets encapsulated in a multi-membrane system 
(encapsulated with layer) were independently assessed. 
FIG. 7 shows the biocompatibility of multi-membrane 
microcapsules in a large animal. The omentum of normal dog 
is shown more than six months after treatment having micro-
capsules loosely adhered to the omentum. 
FIG. 8 illustrates insulin secretion by retrieved encapsu-
lated islets. Islets encapsulated in a multi-membrane micro-
capsule retrieved afterbeing transplanted in a dog at 100 days 
post transplantation were tested in a cell perfusion system. 
FIG. 9 shows blood glucose analysis of canine allotrans-
plantation. The figure is an example of a canine model that has 
undergone a total pancreatectomy. The top panel illustrates 
the venous plasma glucose concentrations collected 12-18 
hours following a meal. The lower panel illustrates the daily 
dosage of subcutaneous porcine insulin administered. 
FIG. 10 depicts the body weight analysis of canine allot-
ransplantation. The top and bottom panels have been 
imported from FIG. 9. The middle panel shows the animal 
body weight monitored during the testing period. 
FIG. 11 illustrates fructosamine analysis of canine allot-
ransplantation. The top and bottom panels have been 
imported from FIG. 9. The middle panel shows fructosamine 
measurements, an indicator of blood glucose level averaged 
over 2-3 weeks in diabetic subjects. 
FIG. 12 shows the re-transplantation of encapsulated islets 
in canine. This chart illustrates an initial allotransplantation 
and re-transplantation on a canine of islets encapsulated in a 
multi-membrane system. 
FIG. 13 depicts the results of the Intravenous Glucose 
Tolerance Test (IVGTT). The chart evaluates intravenous 
dextrose (300 mg/kg) administration in a canine having pre-
viously received a transplantation of islets encapsulated in 
multi-membrane system. 
FIG. 14 is a photograph depicting an immunoisolation 
patch of an embodiment of the present invention, as described 
in Example 7. 
4 
FIG. 15 is a photograph depicting an immunoisolation 
patchbeing heldup on a vertical surface by surface tension, as 
described in Example 7. 
FIG. 16 is a photograph illustrating the surgical placement 
5 of an immunoisolation patch of an embodiment of the present 
invention, as described in Example 8. 
FIG. 17 depicts the pore size distributions of the microcap-
sule membranes of a microcapsule formed according to an 
embodiment of the present invention. 
10 	 FIG. 18 is a photograph depicting an immunoisolation 
patch retrieved from a canine host five months after initial 
transplantation in subcutaneous space, as described in 
Example 10. 
FIG. 19 depicts blood glucose, fructosamine and insulin 
15 analysis, as well as body weight analysis, of a canine having 
an implanted immunoisolation patch, as described in 
Example 10. 
DETAILED DESCRIPTION 
20 
Reference will now be made in detail to the presently 
preferred embodiments of the invention, which, together with 
the drawings and the following examples, serve to explain the 
principles of the invention. These embodiments are described 
25 in sufficient detail to enable those skilled in the art to practice 
the invention, and it is to be understood that other embodi-
ments may be utilized, and that structural, biological, and 
chemical changes may be made without departing from the 
spirit and scope of the present invention. Unless otherwise 
3o defined, all technical and scientific terms used herein have the 
same meaning as commonly understood by one of ordinary 
skill in the art to which this invention belongs. Although any 
methods and materials similar or equivalent to those 
described herein can be used in the practice or testing of the 
35 present invention, the preferred methods, devices, and mate-
rials are now described. 
One skilled in the art may refer to general reference texts 
for detailed descriptions of known techniques discussed 
herein or equivalent techniques. These texts include Current 
40 Protocols in Molecular Biology (Ausubel et al., eds., John 
Wiley & Sons, N.Y., and supplements through July 2007), 
Current Protocols in Immunology (Coligan et al., eds., John 
Wiley & Sons, N.Y., and supplements through August 2007), 
Current Protocols in Pharmacology (Enna et al., eds., John 
45 Wiley & Sons, N.Y., and supplements through June 2007), 
The Pharmacological Basis of Therapeutics (Goodman & 
Gilman, 11 th ed., 2006), Remington: The Science and Prac-
tice of Pharmacy (Lippincott Williams & Wilkins, 21st edi-
tion (2005)), Biomedical Aspects of Drug Targeting (Muzy- 
5o kantov & Torchilin, eds., Springer (2003)), Ophthalmic Drug 
Delivery Systems (A K Mitra, ed., Informa Healthcare, 2" d 
ed. (2003)), Principles and Practice of Ophthalmology (Al-
bert and Jakobiec eds., 2d. ed., W.B. Saunders Company 
(1999)), and Enhancement in Drug Delivery (Touitou & 
55 Barry, eds., CRC Press (2006)) for example. 
The present invention concerns methods and systems for 
the prophylactic and therapeutic treatment of disease via cel-
lular transplantation without the need for immunosuppres-
sion. As shown in FIG. 1, the immunoisolation patch system 
60 10 of the present invention comprises a support matrix 20, in 
which a plurality of multi-membrane microcapsules 30, 
which encapsulate biological material such as cells, are dis-
tributed. The microcapsules encapsulate the biological mate-
rial to be transplanted, and provide stability and immunopro- 
65 tection benefits to the biological material, thus obviating the 
need to use immuno suppressive agents. The support matrix 
provides additional immunoprotection benefits, and retains 
US 8,673,294 B2 
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the microcapsules in proximity to each other and to the site of 	 membrane to not upset the balance between immunoisolation 
implantation, thus improving mass transport and safety while 	 and mass transport of the inner membrane. 
preventing microcapsule migration, diffusion, gravitational 
	
Even if some immune system components pass throughthe 
sedimentation, and clumping. The immunoisolation patch 	 outer membrane, they are still prevented (or at least delayed) 
system is small and easily implanted via minimally invasive 5 from reaching the biological material by the inner membrane, 
(e.g., laparoscopic) surgical techniques. 	 which is thick and has a broad pore size distribution (e.g., it 
The immunoisolation patch system is useful for cellular 	 can contains both large and small pores). The numerous small 
transplantation, particularly for the treatment of chronic dis- 	 pores in the inner membrane trap the immune system com- 
eases and disorders such as endocrine disorders. Although it 	 ponents and act as a barrier membrane. The inner membrane 
is knownto transplant biological material, prior methods have io is designed to provide a proper balance between immunoiso- 
relied either on macro-systems which have limited applica- 	 lation and mass transport. The inner membrane should be 
tions due to safety consideration and invasive surgery for 	 biocompatible with the biological material. The term "bio- 
implantation, or on micro-systems which have drawbacks 	 compatible" as used in this context refers to the capability of 
such as migration, diffusion, gravitational sedimentation, or 	 the implanted composition and its contents to avoid detrimen- 
clumping of biological material. The present system, how-  15 tal effects of the host's various protective systems, such as the 
ever, may be administered with minimally invasive methods, 	 immune system or foreign body fibrotic response, and remain 
the microcapsules individually protect small quantities of 
	
functional for a significant period of time. In addition, "bio- 
biological material, and the support matrix retains the relative 	 compatible" also implies that no specific undesirable cyto- 
location of the microcapsules to prevent undesirable move- 	 toxic or systemic effects are caused by the composition and its 
ment in the subject after implantation. The advantages of the 20 contents such as would interfere with the desired immunoiso- 
immunoisolation patch system are particularly beneficial for 	 lation functionality. The inner membrane should also possess 
intra-peritoneal or subcutaneous implantation, as may be par- 	 sufficient mechanical strength to hold the biological material 
ticularly desirable for the treatment of endocrine disorders. 	 within the membrane and provide immunoprotection from 
A. Multi-Membrane Microcapsules 	 antibodies in the immune system of a host. The small pores of 
The immunoisolation patch of the invention comprises a 25 the inner membrane are designed to prevent or delay most of 
plurality of multi-membrane microcapsules, each of which 	 the immune system from entering the inner sanctum of the 
has the ability to encapsulate biological material. As shown in 	 microcapsule where the cells reside. 
FIG. 2, in a preferred embodiment, a microcapsule 30 com- 	 This combination of the inner and outer membranes with 
prises an inner membrane 34 and an outer membrane 36, 	 different immunoprotection mechanisms protects the bio- 
which surround (encapsulate) a biological material 40. The 30 logical material from being overwhelmed by the immune 
microcapsule may further comprise an additional layer or 	 system. The outer membrane also acts to bond the inner 
layers, such as a membrane, coating, or combination of both. 	 membrane of the microcapsule with the surrounding material 
Each membrane performs at least one function in a manner 	 of the support matrix, preferably through affinity binding. 
that allows the multi-membrane composition to meet the 	 Binding the microcapsule membranes and support matrix 
dichotomy goals of a large-animal transplantation. Although 35 together in this manner provides a crosslinking effect that 
each membrane is designed to allow optimal mass transport 	 creates a tighter and more cohesive immunoisolation patch, 
while maintaining islet health and functionality, no single 	 and eliminates or reduces the possibility of capsule-immu- 
membrane is required to compromise its design to meet the 	 noisolation patch separation. 
multi-faceted dichotomy goals. For instance, increasing the 	 In a preferred embodiment, the immunoisolation patch 
membrane pore sizes to improve mass transfer can jeopardize 40 comprises (a) an inner membrane that is biocompatible with 
microcapsule stability, but increasing polymer concentration 	 the biological material and possesses sufficient mechanical 
to improve microcapsule stability can decrease the mass 	 strength to hold the biological material within the membrane 
transport. These dichotomies can lead to compromises on 	 and provide immunoprotection from antibodies in the 
microcapsule design and performance. To solve this diffi- 	 immune system of a host; (b) an outer membrane that pos- 
culty, each membrane is designed to perform only one or two 45 sesses sufficient chemical stability to reinforce the inner 
specific tasks, and it is the combination of these features in the 	 membrane from the chemicals in the host; and (c) a support 
separate membranes that allows the composition to jointly 	 matrix that is biocompatible with the host and possesses 
function in a manner not afforded by a single membrane. 	 sufficient mechanical strength to shield the inner and outer 
Together, the multi-membrane microcapsule meets most or 	 membranes from non-specific immune response systems in 
all of the dichotomy goals of cellular transplants in a large 50 the immune system of the host. 
animal model without the need for immunosuppression. 	 The relative thickness of the various membranes is selected 
The outer membrane of the microcapsule is a thin interwo- 	 by the practitioner according to the principles discussed pre- 
ven membrane with uniform pores that serves as a gatekeeper 	 viously. Generally, the thicker the membrane, the more 
to keep out most of the high molecular weight immune system 	 mechanical strength is provided. However, when a membrane 
components, such as IgM, while allowing low molecular 55 becomes too thick, mass transport capabilities start to dimin- 
weight oxygen, nutrients, and hormones to pass through with- 	 ish. In a preferred embodiment, the thickness of the inner 
out much impedance. The outer membrane possesses suffi- 	 membrane is selected from a thickness between about 5 to 
cient chemical stability to reinforce the inner membrane and 	 about 100 microns, more preferably from about 10 to about 
the entire microcapsule against chemicals in the host, such as 	 60 microns, and most preferably from about 20 to about 40 
sodium, calcium, magnesium, and potassium ions, as well as 60 microns. In another embodiment, the inner membrane has a 
other chemicals in the host bloodstream. The outer membrane 	 thickness of about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 
is chemically stabile against those chemicals, which allows it 	 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 
to retard the deterioration of the membranes. This prolongs 	 105,110,115, or 120 microns. Ina preferred embodiment, the 
the life of the membranes and consequently the biological 	 thickness of the outer membrane is less than about 5 microns, 
material that is being enclosed by the inner membrane. The 65 preferably about 1-3 microns. In another embodiment, the 
outer membrane also has a relatively uniform pore size, with 	 outer membrane has a thickness of about 0.25, 0.5, 0.75, 1, 
in combination with its thinness can assist in allowing the 	 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, or 6 microns. 
US 8,673,294 B2 
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Any combination of these membrane thicknesses may be 	 interlocking of the two membranes keeps them from separat- 
used, for example in a preferred embodiment, the inner mem- 	 ing inside the hostile environment of the intra-peritoneal of 
brane has a thickness of 10-40 microns, the outer membrane 	 large animals. The outer membrane can also provide imped- 
has a thickness of 1-3 microns, and the immunoisolation 	 ance match for the inner membrane and patch by gradually 
patch has a thickness of 0.6-2.0 mm. In another embodiment, 5 increasing the polycation concentration outwardly to bind the 
the inner membrane may have a thickness of about 60 	 microcapsules to the support matrix of the immunoisolation 
microns, the outer membrane may have a thickness of about 	 patch. 
3 microns, and the immunoisolation patch may have a thick- 	 The composition and size of the microcapsules is selected 
ness of about 0.6-2.0 mm. 	 by the practitioner depending on the desired biological mate- 
In a preferred embodiment, a microcapsule is capable of io rial to be encapsulated, and the therapeutic goals. Preferably, 
encapsulating biological material, and comprises (a) a mem- 	 the microcapsules have an average diameter ranging from 
brane containing sodium alginate, cellulose sulfate, and a 	 about 15 µm to several mm. Larger sizes are generally pre- 
multi-component polycation; and (b) a membrane containing 	 ferred when the biological material is of a type that tends to 
a polycation. The first membrane is preferably the inner mem- 	 aggregate, for example pancreatic islets or thyroid follicles. 
brane, and the second membrane is preferably an outer mem-  15 In a preferred embodiment, the microcapsules have an aver- 
brane. 	 age diameter of about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 
In a preferred embodiment, the first membrane should 
	
70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 
comprise or consist essentially of sodium alginate, cellulose 	 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 
sulfate, and a multi-component polycation. The polycation is 	 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 
preferably a combination of poly(methylene-co-guanidine) 20 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 
and either calcium chloride, sodium chloride, or a combina- 	 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 
tion thereof. This membrane may be the encapsulation system 	 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 
described in U.S. Pat. No. 5,997,900. 	 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 
The second membrane should comprise a polycation. Any 	 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 
suitable biocompatible polycation may be used, and in a 25 1200,1300, 1400,1500, 1600, 1700,1800, 1900, 2000, 2100, 
preferred embodiment the polycation is selected from the 	 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3200, 
group consisting of poly-L-lysine (PLL), poly-D-lysine 	 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4200, 4300, 
(PDL), poly-L,D-lysine, polyethylenimine, polyallylamine, 	 4400, 4500, 4600, 4700, 4800, 4900, or 5000 µm. 
poly-L-ornithine (PLO), poly-D-ornithine, poly-L,D-orni- 	 The microcapsules can comprise additional layers (e.g., 
thine, polyvinylamine, chitosan, cationic polyacrylamide, 30 membranes, coatings, or a combination of both). These addi- 
cationic polyvinyl alcohol, and combinations thereof. More 	 tional layers may provide better or more enhanced features to 
preferably, the polycation is selected from the group consist- 	 those provided by the two-membrane system. The additional 
ing of poly-L-lysine, poly-D-lysine, poly-L,D-lysine, poly- 	 layers can, independently or jointly, provide additional 
L-ornithine, poly-D-ornithine, poly-L,D-ornithine, chitosan, 	 immunoprotection, mechanical strength, chemical stability, 
polyacrylamide, poly(vinyl alcohol), and combinations 35 and/or biocompatibility to the multi-membrane composition. 
thereof. Most preferably, the polycation is poly-L-lysine. The 	 For example, a protective membrane or coating on the outer 
second membrane also preferably comprises at least one 	 surface of the microcapsule may provide additional immuno- 
compound selected from the group consisting of sodium algi- 	 protection, biocompatibility, and mechanical strength to the 
nate, cellulose sulfate, and poly(methylene-co-guanidine). 	 microcapsules. Additional layers may be particularly benefi- 
More preferably, the second membrane comprises or consists 40 cial to use in circumstances where the support matrix may be 
essentially of a polycation and all three compounds. Most 	 subjected to damaging forces, because the additional layers 
preferably, the second membrane comprises or consists 	 can continue to protect individual microcapsules even if the 
essentially of poly-L-lysine, sodium alginate, cellulose sul- 	 support matrix itself is damaged and unable to provide full 
fate, and poly(methylene-co-guanidine). 	 protective benefits to the microcapsules. These optional addi- 
In one embodiment, a microcapsule is capable of encapsu-  45 tional layers may be particularly desirable in applications 
lating biological material, and comprises (a) an inner mem- 	 where the microcapsules are used alone (without a support 
brane comprising or consisting essentially of sodium algi- 	 matrix), because the additional layer or layers may provide 
nate, cellulose sulfate, and a multi-component polycation; 	 similar benefits (e.g., immunoprotection) to the microcap- 
and (b) an outer membrane comprising or consisting essen- 	 sules as the support matrix would. 
tially of a polycation. In a preferred embodiment, the multi- 50 	 The multi-membrane composition was designed to be bio- 
component polycation consists essentially of poly(methyl- 	 compatible, achieve effective mass transport, provide 
ene-co-guanidine) and a salt selected from the group 	 immune protection, provide mechanical strength to the bio- 
comprising calcium chloride, sodium chloride, and combina- 	 logical material, and provide chemical stability. Biocompat- 
tions thereof; and the outer membrane polycation is a polyl- 	 ibility of the capsules depends on shielding the immunogenic 
ysine polycation selected from the group consisting of poly-  55 components of the capsules from the transplantation host. 
L-lysine, poly-D-lysine, and poly-L,D-lysine. In another 	 Long-term biocompatibility of the microcapsule membrane 
embodiment, a microcapsule has two membranes, and com- 	 was demonstrated when examination of encapsulated islets 
prises five components. The five components are sodium 	 transplanted into a healthy dog for six and a half months 
alginate (SA), cellulose sulfate (CS), polymethylene-co- 	 revealed no complications. 
guanidine (PMCG), calcium chloride (CaCl2), and poly-L-  60 	 Microcapsules can be made with a droplet generator and a 
lysine (PLL); the outer membrane comprises or consists 	 chemical reaction chamber, such as that described in U.S. Pat. 
essentially of PMCG-CS/PLL-SA, and the inner membrane 	 No. 5,260,002 or 6,001,312. Another droplet generator sys- 
comprises or consists essentially of PMCG-CS/CaC1 2 -SA. 	 tem is a duo syringe system in which two or more syringes are 
In some embodiments, for example when the outer mem- 	 connected in parallel and submerged in a temperature bath to 
brane comprises PLL and the inner membrane comprises SA, 65 keep the living cells healthy. The temperature bath containing 
the PLL component of the outer membrane forms permanent 	 the syringes may be an ice water bath having a temperature at 
bonds with the SA component of the inner membrane. This 	 about 4 degrees C., which aids in keeping the cells in a 
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dormant state. It has been found that islets, when in a dormant 
state, incur less damage during the transplantation process. 
This duo syringe system provides continuous operation by 
allowing for the refilling of one syringe while the experiment 
is ongoing with the other syringe. The syringes may also 5 
contain slow-turning propellers located inside the syringes 
that assist in maintaining islet density uniformity; i.e., more 
even distribution of the islets in the syringe. 
The chemical reaction apparatus includes a multi-loop 
10 
chamber reactor that is filled with solution, such as a cation  
solution. This cation solution bath is fed by a cation stream, 
which continuously replenishes the solution and carries away 
the anion drops being introduced into the chamber. Continu-
ous SACS droplets can stream from the drop generator, with 15 
pancreatic islets enclosed, and enter the cation stream at a 
designated height and angle; so as to reduce or minimize islet 
decentering, drop deformation, and air bubble entrainment 
problems associated with impact. The droplets are then car-
ried into the multi-loop reactor by the polycation stream. The 20 
reactor assists in controlling the time of complex formation as 
well as negating certain gravitational sedimentation effects. 
The capsules are carried into a second loop reactor with the 
same or different polycation solution for continuous opera-
tion. This facilitates tighter control of microcapsule diameter 25 
and sphericity as well as membrane thickness and uniformity. 
Capsules may be produced with diameters ranging from 
about 0.5 mm to about 3.0 mm and membrane thicknesses 
ranging from about 0.006 mm to about 0.125 mm. 
The following tests can be performed to optimize the 30 
microcapsule and the immunoisolation patch as a whole. 
Because all the components should work together, it can be 
difficult to predict how one component will affect another 
after the immunoisolation patch has been fabricated. For 
instance, the process of forming the outer membrane can alter 35 
the performance of the inner membrane. Likewise, the pro-
cess of forming the support matrix can alter the performances 
of the microcapsule membranes. Additionally, advance char-
acterization of each component individually does not predict 
how the multi-membrane capsules or immunoisolation 40 
patches will function together inside transplantation hosts. 
For these reasons, immunoisolation patch formation was 
treated and tested as a total system with multiple parameters, 
e.g., mass transport, immune protection, biocompatibility, 
sphericity/centering, stability etc. 45 
The mechanical strength of capsules may be measured by 
placing an increasing uniaxial load on the microcapsule until 
the microcapsule burst or totally compressed to a flat disc. 
The mechanical strength of the microcapsule, a function of 
membrane composition and thicknesses, can be adjusted any- 50 
where from a fraction of a gram to many tens of grams load to 
meet the transplantation goals without significantly altering 
the permeability of the microcapsule. Stability of the capsules 
depends largely on the stability of chemical bonds and the 
membrane thickness. The intra peritonea fluid of a large ani- 55 
mal such as dog can react chemically with the microcapsule 
membrane and thus weaken the mechanical strength. 
FIG. 3 illustrates the mechanical strength of capsules of 
two different polymer concentrations by plotting the rupture 
load versus the microcapsule membrane thickness and size. 60 
The slope of the curve represents the rupture stress and 
thereby indirectly the inherent strength of the capsular mem-
brane. The chart measures mechanical burst strength of cap-
sules by placing them on a uniaxial load. The solid circles 
represent 0.6-0.6 alginate-CS capsules, the open circles rep- 65 
resent 0.9-0.9 alginate-CS capsules, and the solid square rep-
resents a PLL-alginate system. As can be seen in the chart,  
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while certain polymers are stronger than others, it is generally 
observed that thicker membranes tend to be stronger mem-
branes. 
FIG. 4 illustrates the mechanical strength of two capsules 
with different chemical compositions and membrane thick-
ness. The stability was experimentally determined by mea-
suring the length of time for the capsules to lose its mechani-
cal strength by a factor of 1/e incubated in dog serum at 40 
degrees C. It is believed that a properly designed microcap-
sule system can last years in a hostile environment of perito-
nea of a large animal. In FIG. 4, microcapsule mechanical 
strength was measured as a function of time as the capsules 
were incubated in dog serum at 40 degrees C. The solid 
diamond represent 0.6-0.6 alginate-CS capsules, the solid 
squares represent 0.9-0.9 alginate-CS capsules, and the open 
squares represent 0.6-0.6 alginate-CS capsules. Stability is 
shown by the least amount of fluctuation over time. In the 
chart, the 0.6-0.6 alginate-CS capsules showed the least 
amount of fluctuation and would thus be considered the most 
stable capsules of the three tested. 
In general, the microcapsule is designed to maximize both 
immune protection and mass transport, but the immune pro-
tection goal is inversely proportional to the mass transport 
goals. It is possible to adjust the parameters to satisfy both 
goals simultaneously, however, because their power depen-
dences on membrane thickness and pore size are sufficiently 
different. T. Wang "New Technologies for Bioartificial 
Organs." Arti£ Organs 22(1):68-74 (1998). The membrane 
pore size can be measured using a size exclusion chromatog-
raphy (SEC) method. Brissova et al. "Control and measure-
ment ofpermeability for design of microcapsule cell delivery 
system" J. Biomed. Mat. Res. 39:61-70 (1998). SEC mea-
sures the exclusion of dextran solutes from the column 
packed with microcapsules, and using the measured values of 
solute size exclusion coefficients (KSEC) and known size of 
solute molecules, the membrane pore size distribution and 
microcapsule permeability can be determined. FIG. 5 dem-
onstrates the pore size distribution of a microcapsule mem-
brane with a cutoff of 80 KDa (about 12 nanometers in diam-
eter). This pore size is large enough for glucose and insulin to 
enter and exit, and small enough to keep the immune system 
from penetrate all the way to the core of the capsules where 
biological material reside. The chart illustrates normalized 
retention time as a function of pore size distribution of micro-
capsule membrane. 
B. Immunoisolation Patch Systems 
The microcapsules of the invention are distributed in a 
support matrix to form an immunoisolation patch. The sup-
port matrix retains the microcapsules in proximity to each 
other and to the site of implantation, thus preventing micro-
capsule migration, diffusion, gravitational sedimentation, 
and clumping. It also provides strength to the immunoisola-
tion patch to permit its implantation, removal, re-implanta-
tion or transplantation, and the like. The support matrix can be 
based on any biologically suitable material, and preferably is 
sufficiently biocompatible with the host such that the host 
does not treat the patch as a foreign object and reject it or 
attempt to destroy it. The support matrix (and accordingly the 
immunoisolation patch) may take a variety of shapes and 
sizes, for example it may be circular, oval, oblong, triangular, 
rectangular, pentangular, etc. The support matrix must not 
alter the performances of the capsules. The support matrix is 
preferably flexible, so that the immunoisolation patch can 
conform to the surface contour of the implantation site, and 
form intimate contact with the tissue at the implantation site 
to deliver the bioactive agent, so as to receive oxygen, nutri-
ents, and the like for delivery to the biological material inside 
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the microcapsules. A schematic of an exemplary immunoiso- 	 antibody IgM, which has a molecular weight of about 300 
lation patch is shown in FIG. 1. 	 kilodaltons (kDa), can be particularly deadly if it breaches the 
Generally, the support matrix provides additional immu- 	 microcapsules. In view of these known antibodies, the poros- 
noprotection to the microcapsules from the host immune 	 ity cutoff (i.e., the considerable drop off of the number of 
system, improves the biocompatibility of the microcapsule 5 pores larger than the cutoff size) of the immunoisolation 
and can also provide additional mechanical strength for sta- 	 patch should be less than 300 kDa. Preferably, because mem- 
bility as well as immune protection. The immunoisolation 	 branes are often formulated as a random network system, the 
patch also should possess sufficient mechanical strength to 	 porosity cutoff is preferably below about 100 to 150 kDa. 
shield the microcapsules from the non-specific innate 	 This better assures that the designed membrane contains very 
immune system of the host. The innate immune system, io few or no pores larger than 300 kDa. On the other hand, the 
which includes neutrophils, macrophages, dendritic cells, 	 porosity cutoff should be larger than about 50 kDa to ensure 
natural killer cells, and others, when activated, can attack the 	 that bioactive agents released by the biological material have 
multi-membrane composition or microcapsule by engulfing 	 the ability to be freely released from the immunoisolation 
it. It can also stimulate the activities of antibodies to attack the 	 patch. The porosity cutoff preferably ranges from about 50 
islets inside of the composition. 	 15 kDa to about 250 kDa to permit the passage of molecules 
The support matrix can be a synthetic polymer-based 
	
having a molecular weight less than about 50 kDa while 
matrix, or a biopolymer-based matrix. In a preferred embodi- 	 preventing the passage of molecules having a molecular 
ment, the support matrix comprises a natural material, pref- 	 weight greater than about 250 kDa. 
erably natural polymers, which can provide lubrication as 	 In one embodiment of the invention, each component (e.g., 
well as mechanical strength. Suitable biopolymeric materials 20 microcapsule inner membrane, microcapsule outer mem- 
include, but are not limited to, proteins (e.g., collagen, gela- 	 brane, support matrix) of the immunoisolation patch has 
tin, fibrin, elastin, or silk) and polysaccharides (e.g., hyalu- 	 about the same porosity. In this embodiment, the porosity 
ronic acid, alginic acid, alginate, cellulose, chitin). In a pre- 	 cutoff is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100,110, 
ferred embodiment, the support matrix is formed from one or 	 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 
more biocompatible polymers, and preferably comprises a 25 240, 250, 260, 270, 280, 290, 300, 310, 320, or 330 kDa, and 
carbohydrate polymer having carboxylate or sulfate groups. 	 more preferably is 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 
The carbohydrate polymer preferably is selected from the 	 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 
group consisting of sodium carboxymethyl cellulose, low 	 220, 230, 240, 250, 260 kDa. More preferably, the porosity 
methoxy pectins, sodium alginate, potassium alginate, cal- 	 cutoff ranges from about 80 kDa to about 150 kDa. In another 
cium alginate, tragacanth gum, sodium pectate, kappa carra-  30 embodiment of the invention, each component has a different 
geenans, and iota carrageenans. More preferably, the carbo- 	 porosity. Having components of varying porosity assists, 
hydrate polymer is selected from the group consisting of 	 among other areas, in mass transport and immunoprotection. 
sodium alginate, potassium alginate, and calcium alginate. 	 In this embodiment, the porosity cutoff of the inner mem- 
Most preferably, the carbohydrate polymer is sodium algi- 	 brane is 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 
nate. 	 35 110, 115, 120, 125, 130, 135, 140, 145, 150, 155 or 160 kDa, 
The support matrix may also comprise an inorganic metal 	 more preferably in the range of about 50 to about 150 kDa, the 
salt. Suitable metal salts include calcium chloride, magne- 	 porosity cutoff of the outer membrane is 90, 95, 100, 110, 
sium sulfate, manganese sulfate, calcium acetate, calcium 	 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, or 220 kDa, 
nitrate, ammonium chloride, sodium chloride, potassium 	 more preferably in the range of about 100 to about 200 kDa, 
chloride, choline chloride, strontium chloride, calcium glu-  4o and the porosity cutoff of the support matrix is 140, 150, 160, 
conate, calcium sulfate, potassium sulfate, barium chloride, 	 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 
magnesium chloride, and combinations thereof. Preferably, 	 290, 300, 310, 320, 330, 340, or 350 kDa, more preferably in 
the inorganic metal salt is selected from the group consisting 	 the range of about 150 to about 250 kDa. 
of calcium chloride, ammonium chloride, sodium chloride, 	 In an embodiment of the invention, each component (e.g., 
potassium chloride, calcium sulfate, and combinations 45 microcapsule inner membrane, microcapsule outer mem- 
thereof. Most preferably, the inorganic metal salt is calcium 	 brane, support matrix) of the immunoisolation patch has a 
chloride. 	 narrow pore size distribution, i.e., the pores are of relatively 
In a preferred embodiment, the immunoisolation patch 	 uniform size. In a preferred embodiment, the narrow pore size 
comprises a plurality of microcapsules, at least some of which 
	
distribution is characterized by the relation (dso-d,,)/dso 
comprise (a) an inner membrane that is biocompatible with 5o being less than 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 or 0.05, 
the biological material and possesses sufficient mechanical 	 wherein the value d,, is the pore diameter at which 10% of the 
strength to hold the biological material within the membrane 	 pores are finer, based upon volume, and d so is the median pore 
and provide immunoprotection from antibodies in the 	 diameter. Preferably, the relation (dso-d,,)/dso  is less than 
immune system of a host, and (b) an outer membrane that 	 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, 0.1 or 0.05. 
possesses sufficient chemical stability to reinforce the inner 55 	 In another preferred embodiment, the pore size distribution 
membrane from the chemicals in the host; and a support 	 of the microcapsule inner membrane is broader than the pore 
matrix that is biocompatible with the host and possesses 	 size distribution of the microcapsule outer membrane, for 
sufficient mechanical strength to shield the inner and outer 	 example the relation (d,,-d, ,)/d,, of the inner membrane can 
membranes from non-specific immune response systems in 	 be less than 0.5 but greater than 0.3, and the relation (d,,- 
the immune system of the host. 	 6o d,,)/d,, of the outer membrane can be less than 0.3. In this 
The immunoisolation patch composition has a porosity 	 embodiment, the combination of the different pore size dis- 
that is sufficiently large enough to allow for the release of 	 tributions of the different components allows for finer adjust- 
bioactive agents from the biological material but sufficiently 	 ments of membrane performance, in that the membranes are 
small enough to prevent the entry of antibodies from an 	 able to exclude harmful substances such as IgM from entering 
immune system. There are known antibodies that destroy 65 without overly hampering mass transport. FIG. 17 depicts the 
living cells that should, when possible, be prevented from 	 pore size distribution of such an exemplary microcapsule, in 
entering the multi-membrane composition. For instance, the 	 which the pore size distribution of the microcapsule inner 
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membrane (dotted line) is broader than the pore size distri-
bution of the microcapsule outer membrane (solid line). The 
apparent PSD of the capsule membranes was determined by 
the exclusion of dextran solutes (KSeC) measurements. The 
vertical axis (1—KSeC) approximates pore density of a given 
size. 
The immunoisolation patch may comprise one or more 
layers of microcapsules. In a preferred embodiment, a mono-
layer of microcapsules is used, so that each microcapsule can 
easily participate in mass transport and allow oxygen, nutri-
ents, and hormones to pass through for recipient health. Pref-
erably, the microcapsules are distributed relatively uniformly 
throughout the support matrix, and are spaced far enough 
apart to reduce the possibility of hypoxia caused by cells 
being too close to each other. A relatively thin patch is also 
desirable to maintain patch flexibility, and to provide a large 
surface area so that the patch can be kept in place at the 
implantation site. 
The relative size and shape of the immunoisolation patch 
can be selected by the practitioner according to parameters 
such as the desired implantation site, the therapeutic applica-
tion, etc. In a preferred embodiment, the diameter of the patch 
is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 
18, 19, or 20 cm, preferably about 1-10 cm, and more pref-
erably about 3-7 cm, and the thickness of the patch is about 
0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75 or 3 mm 
thick, preferably about 0.5 to 2 mm thick, and more prefer-
ably about 1 mm thick. In a preferred embodiment, the immu-
noisolation patch is about 6 cm in diameter, and about 1 mm 
thick. In a preferred embodiment, the immunoisolation patch 
has a thickness of about 0.4-2.5 mm, more preferably about 
0.5-2.2 mm microns, and even more preferably about 0.6-2.0 
mm microns. 
C. Methods of Treatment 
Depending on the disorder to be treated, the microcapsules 
can be loaded with any suitable biological material. The bio-
logical material may be any material that is a capable of being 
encapsulated by a membrane, and preferably is cellular mate-
rial, e.g., cells or groups of cells such as acini, follicles, islets, 
and the like. Typically, the biological material is a cell or 
group of cells or tissue that can provide a subject with some 
therapeutic result when introduced into the subject, for 
example the release of a bioactive agent. The type of cell(s) 
will vary depending on the disorder to be treated, as is evident 
to those skilled in the art. For example, in the treatment of 
liver failure, hepatocytes can be loaded into the microcap-
sules, and in the treatment of diabetes, pancreatic cells (of one 
or more types) can be loaded into the microcapsules. The cells 
may be of the same type or a different type than the native 
tissue at the site of implantation. For example, in the treat-
ment of a neurological disorder in a human, human neuronal 
cells may be administered, or non-human cells, such as PC12 
cells derived from rats, may be administered. 
Cells from a variety of sources can be used, including but 
not limited to autografts (host stem-cell derived), allografts 
(either primary cells or stem-cell derived), xenografts (por-
cine cells or others), or genetically engineered cells. Human 
biological material, or biological material derived from 
humans, may be desired if the subject is human, butbiological 
material from other sources, for example cows, pigs, rats, 
sharks and sheep, may be used. The biological material may 
be obtained from any suitable source, for example research 
laboratories, local slaughterhouses, cell cultures, donor tis-
sue, and the like. The number of cells within each microcap-
sule can be readily controlled by means known to the skilled 
practitioner. For example, the density of a cell suspension can 
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be varied during formation of the microcapsules to afford 
microcapsules with varied numbers of cells encapsulated 
within. 
In a preferred embodiment, the biological material is cel- 
5 lular material selected from the group consisting of pancre-
atic islets, hepatocytes, choroid plexuses, neurons, parathy-
roid cells, and cells secreting clotting factors. In a preferred 
embodiment for the treatment of diabetes, the cellular mate-
rial is pancreatic beta cells, pancreatic islets (Islets of Langer- 
io hans), or other insulin-producing islets capable of treating a 
patient suffering from diabetes. In a preferred embodiment 
for the treatment of a pancreatic exocrine disorder, the cellu-
lar material is centroacinar cells, pancreatic basophilic cells, 
or acini. In a preferred embodiment for the treatment of a 
15 pituitary disorder, the cellular material is a cell of the anterior 
pituitary gland. 
The bioactive agent is any agent that can be released or 
secreted from the biological material. For example, pancre-
atic islets have the capability of secreting the bioactive agent 
20 insulin; choroid plexuses have the capability of secreting 
cerebral fluids; neurons have the capability of secreting 
agents such as dopamine that can effect the nervous system; 
and parathyroid cells have the capability of secreting agents 
that can effect metabolism of calcium and phosphorus in a 
25 subject. Preferably, the bioactive agent is a hormone or neu-
rotransmitter. In a preferred embodiment for treatment of a 
pancreatic disorder, the bioactive agent is selected from the 
group consisting of gastrin, glucagon, insulin, pancreatic 
polypeptide, and somatostatin, and preferably is insulin. In 
3o another preferred embodiment for treatment of a pancreatic 
disorder, the bioactive agent is selected from the group con-
sisting of chymotrypsin, pancreatic amylase, pancreatic 
lipase, and trypsin. In a preferred embodiment for treatment 
of a thyroid disorder, the bioactive agent is selected from T  
35 T2, T3, T4, and calcitonin. In a preferred embodiment for 
treatment of a neurological disorder, the bioactive agent is a 
neurotransmitter, and preferably is dopamine. 
The various embodiments of the present invention have a 
wide variety of therapeutic and prophylactic uses in the area 
40 of cell therapy or cellular transplantation, for example in the 
treatment of age-related disorders, allergic disorders, autoim-
mune diseases, cancers, endocrine disorders, immune disor-
ders, inflammatory disorders, neurological disorders, organ 
failure, proliferative disorders, other conditions involving tis- 
45 sue injury, and other conditions wherein replacement cells are 
desirable. 
As known in the art, cell therapy is the transplantation of 
human or animal cells to replace or repair damaged or mal-
functioning tissues, and/or cells. The types of cells that are 
5o administered correspond in some way with the organ or tissue 
in the patient that is failing. For example, in the context of a 
subject suffering from diabetes or related disorders, cell 
therapy treatment involves the transplantation of insulin-pro-
ducing cells that can replicate the function of pancreatic cells 
55 and release insulin into the subject upon the advent of certain 
conditions, namely an elevated glucose level in the subject. 
The cells can be introduced through implantation, transplan-
tation, injection or other means known in the art. 
The administration of the patches of the present invention 
60 may be for a "prophylactic" or "therapeutic" purpose. The 
administration is said to be for a "therapeutic" purpose if the 
amount of biological material administered is physiologically 
significant to provide a therapy for an actual manifestation of 
the disease. When provided therapeutically, the patch is pref- 
65 erably provided at (or shortly after) the identification of a 
symptom of actual disease. The therapeutic administration 
serves to attenuate the severity of such disease or to reverse its 
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progress. The administration is said to be for a "prophylactic" 
	
including but not limited to amenorrhea, infertility, hypogo- 
purpose if the amount of biological material administered is 	 nadism, gonadotropin deficiency, Kallmann syndrome, 
physiologically significant to provide a therapy for apotential 
	
Klinefelter syndrome, menopause, menstrual function disor- 
disease or condition. When provided prophylactically, the 	 ders, ovarian failure, polycystic ovary syndrome, testicular 
patch is preferably provided in advance of any symptom 5 failure, and Turner syndrome; and thyroid disorders, includ- 
thereof. The prophylactic administration serves to prevent or 	 ing but not limited to hyperthyroidism, hypothyroidism, and 
attenuate any subsequent advance of the disease. 	 thyroiditis, for example acute thyroiditis, De Quervain thy- 
Providing a therapy or "treating" refers to any indicia of 	 roiditis, Graves-Basedow disease, Hashimoto's thyroiditis, 
success in the treatment or amelioration of an injury, pathol- 	 Hashitoxicosis, iatrogenic hyperthyroidism, iatrogenic 
ogy or condition, including any objective or subjective io hypothyroidism, Ord's thyroiditis, postoperative hypothy- 
parameter such as abatement, remission, diminishing of 	 roidism, postpartum thyroiditis, silent thyroiditis, thyroid 
symptoms or making the injury, pathology or condition more 	 storm, toxic nodular struma (Plummer's disease), and toxic 
tolerable to the patient, slowing in the rate of degeneration or 	 thyroid nodule. 
decline, making the final point of degeneration less debilitat- 	 Exemplary cancers of the endocrine organs that may be 
ing, or improving a patient's physical or mental well-being. 15 treated by various embodiments of the present invention 
The treatment or amelioration of symptoms can be based on 	 include, but are not limited to adrenal hyperplasia or neopla- 
objective or subjective parameters, including the results of a 	 sia, adrenocortical carcinoma, insulinoma, pituitary tumors 
physical examination, neuropsychiatric exams, and/or a psy- 	 such as pituitary adenomas, prolactinoma (or hyperpro- 
chiatric evaluation. For example, the methods ofthe invention 	 lactinemia), acromegaly (gigantism), and Cushing's disease, 
successfully treat a patient's diabetes by stabilizing the 20 thyroid tumors such as thyroid adenoma, anaplastic thyroid 
patient's blood glucose levels, which is evident upon admin- 	 cancer, follicular thyroid cancer, medullary thyroid cancer, 
istration of a blood glucose assay. 	 and papillary thyroid cancer, and endocrine tumor syndromes 
Preferred subjects for treatment include animals, most 	 such as Carney Complex, McCune-Albright syndrome, von 
preferably mammalian species such as humans, and domestic 	 Hippel Lindau syndrome (VHL syndrome), and multiple 
animals such as dogs, cats and the like, subject to disease and 25 endocrine neoplasia (multiple endocrine adenomatosis) or 
other pathological conditions. A "patient" refers to a subject, 	 MEN syndromes such as Wermer syndrome (MEN 1), Sipple 
preferably mammalian (including human), and preferably a 	 syndrome (MEN 2A), MEN 213, and FMTC. 
large mammal. In a preferred embodiment, the patient is a 	 In a preferred embodiment, the disorder to be treated is 
human. 	 diabetes, including but not limited to, Type 1 diabetes, Type  
In a preferred embodiment, the immunoisolation patch is 3o diabetes, maturity-onset diabetes of the young (MODY), 
used as a hormone-producing system, which can be used to 	 latent autoimmune diabetes adult (LADA), impaired glucose 
treat, e.g., an endocrine disorder. For example, a pancreatic 	 tolerance (IGT), impaired fasting glucose (IFG), gestational 
disorder can be treated by implanting an immunoisolation 	 diabetes, and metabolic syndrome X. Preferably, the disorder 
patch comprising one or more types of pancreatic tissue or 	 to be treated is Type 1 diabetes or Type 2 diabetes. 
cells such as alpha cells, beta cells, centroacinar cells, delta 35 	 A variety of administration routes for the compositions of 
cells, epsilon cells, pancreatic basophilic cells, PP cells (F 	 the present invention are available. The particular mode 
cells), acini, or Islets of Langerhans into a patient. Similarly, 	 selected will depend, of course, upon the particular biological 
a thyroid disorder can be treated by implanting an immu- 	 material selected, whether the administration is for preven- 
noisolation patch comprising one or more types of thyroid 	 tion, diagnosis, or treatment of disease, the severity of the 
tissue such as thyroid epithelial cells (follicular cells), 40 medical disorder being treated and the desired therapeutic 
parafollicular cells, or follicles into a patient. 	 efficacy. The duration of prophylactic and therapeutic treat- 
Exemplary endocrine disorders that may be treated by 	 ment will also vary depending on the particular disease or 
various embodiments of the present invention include, but are 	 condition being treated. Some diseases lend themselves to 
not limited to adrenal disorders, including but not limited to 	 acute treatment whereas others require long-term therapy. 
adrenal insufficiencies such as Addison's disease, congenital 45 Generally, the immunoisolation patches are surgically 
adrenal hyperplasia (adrenogenital syndrome), and mineralo- 	 implanted, for example laparoscopically, into an appropriate 
corticoid deficiency, Conn's syndrome, Cushing's syndrome, 	 location in the body, and may be loosed placed therein or 
and pheochromocytoma; autoimmune polyendocrine syn- 	 affixed to the surrounding tissue. For example, an immu- 
dromes, including but not limited to Type 1 autoimmune 	 noisolation patch used for the treatment of diabetes may be 
polyendocrine syndrome, Type 2 autoimmune polyendocrine 50 surgically placed intra-peritoneally in the abdomen and on 
syndrome (Schmidt's syndrome), and immunodysregulation 	 the surface of the omentum, or in subcutaneous locations. 
polyendocrinopathy enteropathy X-linked syndrome (IPEX 	 In an embodiment for the treatment of diabetes or related 
or XPID); glucose homeostasis disorders, including but not 	 disorders, a method of treatment comprises implantation of 
limited to diabetes mellitus, hypoglycemia, and idiopathic 	 an immunoisolation patch comprising multi-membrane 
hypoglycemia; metabolic bone diseases, including but not 55 microcapsules encapsulating insulin-producing islet cells 
limited to osteoporosis, osteitis deformans (Paget's disease of 	 that provides a sustained release of insulin for at least 30 days. 
bone), rickets and osteomalacia; pancreatic disorders, includ- 	 The patch does not exhibit significant degradation during the 
ing but not limited to diabetes mellitus, exocrine pancreatic 	 sustained-release period. The term "sustained release," as 
insufficiency, hypoglycemia, pancreatitis, and Shwachman- 	 used herein, refers to the continual release of the biological 
Diamond Syndrome; parathyroid gland disorders, including 6o agent from the biological material during instances when the 
but not limited to primary hyperparathyroidism, secondary 	 release should take place. For instance, if the biological mate- 
hyperparathyroidism, tertiary hyperparathyroidism, hypo- 	 rial is a pancreatic islet and the biological agent is insulin, the 
parathyroidism, and pseudohypoparathyroidism; pituitary 	 pancreatic islets should, after transplantation, continually 
gland disorders, including but not limited to diabetes insipi- 	 release insulin into the host any time the pancreatic islets 
dus, growth hormone deficiency, hypopituitarism (or panhy-  65 recognize that the glucose level of the host has reached a 
popituitarism), Sheehan syndrome, and syndrome of inap- 	 certain point. After the glucose level in the host has been 
propriate antidiuretic hormone; sex hormone disorders, 	 maintained, the pancreatic islets will temporarily cease 
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secreting additional insulin. However, when the glucose lev-
els in the host again reach a point where insulin is needed, the 
temporarily-dormant pancreatic islets will again begin to 
secrete insulin. This type of continual release is an example of 
sustained release. 
The sustained-release period should last at least 30 days. 
Preferably, it lasts at least 60 days; more preferably, at least 
120 days; and most preferably, at least 180 days. The longer 
the composition is able to provide a sustained release of 
insulin, the longer the patient will be functioning on the cell 
therapy treatment alone without needing additional treat-
ment. For instance, if the cell therapy treatment is able to last 
for at least 180 days, a patient will only need to receive a 
booster treatment approximately once every six months. This 
allows a diabetic patient a significantly increased amount of 
freedom to pursue daily activities without having to continu-
ally monitor their disorder and correct for high or low blood 
sugars and take insulin by injection or otherwise to counter-
balance carbohydrate intake and regular and continual release 
of glucose into the bloodstream by the liver. This will also 
allow for overall greater glycemic control by reducing the 
occurrence of insulin shock or ketoacidosis as well as pre-
venting or delaying the onset of diabetic related complica-
tions. 
This invention also relates to a method of stabilizing the 
glucose level in a patient for at least 30 days, comprising 
administering to a patient suffering from diabetes or related 
disorders an immunoisolation patch containing multi-mem-
brane microcapsules encapsulating insulin-producing islet 
cells. The method can stabilize the glucose level for at least 30 
days; preferably, at least 60 days; more preferably, at least 120 
days; and most preferably, at least 180 days. 
Application of the teachings of the present invention to a 
specific problem or environment is within the capabilities of 
one having ordinary skill in the art in light of the teachings 
contained herein. Examples of the products and processes of 
the present invention appear in the following examples. 
Example 1 
Pancreatic Islet Isolation and Evaluation 
For the isolation of pancreatic islets, mongrel canines (20-
28 kg body weight) were placed under general anesthesia 
following an 18-hour fast. A midline laparotomy was per-
formed. The gastroduodenal, splenic and pancreaticoduode-
nal veins and arteries were isolated and a ligature was placed 
around each vessel. The main pancreatic duct was identified 
at the point of duodenal entry and dissected. A ligature was 
placed around the duct. An 18-gauge angiocath was inserted 
into the duct and the tip advanced 2-3 mm such that it 
remained in the main ductal architecture just prior to ductal 
branching in the pancreas. The catheter was sutured to the 
duct to secure its position. Immediately prior to harvest, the 
previously placed vascular ligatures were tightened and the 
animal was euthanized. The pancreas was transected from all 
peritoneal and vascular attachments and dissected from the 
duodenum. Once excised, the pancreas was immediately per-
fused with ice-cold University of Wisconsin (UW-D) perfu-
sion solution via the previously placed ductal catheter. 
A visual inspection was performed to ensure that the entire 
pancreas is perfused. The harvested glands were transported 
on ice to the laboratory where the UW-D solution was 
replaced by a solution of collagenase in UW-D (Crescent 
Chemical). The glands were then placed in a shaking water 
bath and digested at 40° C. for approximately 35 minutes. The 
dissociated tissue was filtered through a 400 µm mesh screen 
18 
and washed several times with ice-cold media to remove and 
inactivate the collagenase. Based on density differences 
between islets and exocrine tissue, a discontinuous ficoll gra-
dient was used to separate the islets and exocrine tissue. After 
5 density centrifugation, the islets were collected, washed, and 
transferred to tissue culture M199 media supplemented with 
10% FBS (Fetal Bovine Serum) and antibiotics. During cul-
ture for 48-72 hours, isolated islets maintained their compact 
appearance and the microcapsule surface remained smooth. 
10 Islet isolations were performed on 56 canine pancreases. A 
profile of the average isolation results per pancreas is shown 
below (islets fragments that are smaller than 50 µm are not 
quantified). In addition to the number of islets isolated, the 
15 quality of isolations was evaluated by determining the islet 
diameter, purity, islet viability, and islet function. Since the 
average islet diameter will vary, the isolation yield is normal-
ized by computing the ratio of the average islet volume and 
the volume of a "standard" islet of 150 µm in diameter. The 
20 resulting value is referred to as the Equivalent Islet Number 
(EIN) and allows a yield-comparison for different isolations. 
Islet purity was determined from a sample that was stained 
with the islet-specific dye dithizone. The dye stains islets red 
but leaves exocrine tissue unstained. Most of the exocrine 
25 tissue dies during the first 24 hrs of culture, resulting in an 
increase in purity during culture to approximately 95%. 
Islet viability is determined from a sample that was stained 
with a combination of Calcein AM (stains live cells fluores-
cent green) and Ethidium Bromide (stains the nuclei of dead 
30 cells fluorescent red). Viability is scored on a scale of 1 (all 
cells dead) to 4 (all cells alive). The average of five typical 
isolations is tabulated below. 
35 
Islets per pancreas 435 ± 38K 
Islet Diameter 106 ± 3.8 µm 
Islet Equivalent Number 0.48 ± 0.04 
Purity 87.3 ± 1.2 
Viability 3.5 ± 0.1 
40 
Example 2 
Microcapsule Formation 
45 
A series of capsules having a range of permeability (poros-
ity cutoff ranging from 40 kDa-230 kDa, based on dextran 
exclusion measurement) was developed and characterized. 
The apparent pore size of the capsular membrane was deter- 
50 mined by size exclusion chromatography (SEC) that mea-
sures the exclusion of dextran solutes from a column packed 
with microcapsules. Measuring permeability as a function of 
polymer component concentration and chemical reaction 
time allowed adjustment of microcapsule permeability in a 
55 controlled manner. Two-membrane microcapsule was 
formed. The outer membrane with strong ionic bonds formed 
a thin membrane with narrow pore size distributions. It has a 
porosity of —100 kDa and thickness of —1 micron. The inner 
membrane of this capsule is thicker and its pore size has broad 
6o distributions. It has a porosity of approximately 150 kDa and 
thickness of 20-40 microns. 
Three-membrane microcapsules were also formed, in 
which the inner membrane has a porosity of approximately 
150 kDa and thickness of 20-40 microns, the outer membrane 
65 has a porosity of approximately 100 kDa and thickness of 1-3 
microns, and the additional (outermost) membrane has a 
porosity of approximately 250 kDa and thickness of 100-300 
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microns. Also formed were three-layered microcapsules hav-
ing these porosity and thickness ranges, in which the inner 
membrane is PMCG-CS/CaCl z -SA, the outer membrane is a 
thin interwoven PMCG-CS/PLL-SA, and the additional 
membrane is CaCl 2-SA. 
Example 3 
Encapsulation of Pancreatic Islets and Testing 
Pancreatic islets were isolated as described in Example 1, 
and following islet isolation, diameter, purity, and viability 
testing, the islets were cultured for 48-72 hours and encapsu-
lated with a multi-membrane microcapsule of Example 2. 
The insulin secretory capacity of the free islets and encapsu-
lated islets was then determined in a cell perfusion system. 
Insulin secretion by encapsulated islets was evaluated in a 
cell perfusion apparatus with a flow rate of 1 ml/minute with 
RPMI 1640 with 0.1% BSA as a perifusate. Encapsulated 
islets were perifused with 2 mM glucose for 30 minutes and 
the column flowthrough discarded. Three minute samples of 
perifusate were collected during a 30 minute perfusion of 2 
mM glucose, a 30 minute perfusion of 20 mM glucose+0.045 
mM IBMX (a nutrient), and a 60 minute perfusion of 2 mM 
glucose. Samples were assayed in duplicate for insulin using 
Coat-a-Count kits (Diagnostic Products Corporation, Los 
Angeles, Calif.) with a canine insulin standard. The amount 
of insulin secreted was normalized for the number of islets. 
As assessed by the dynamic response to insulin secreta-
gogues, insulin secretion by encapsulated islets had a similar 
profile as unencapsulated free islets with a slightly delay in 
insulin secretion, as shown in FIG. 6. This delay in insulin 
secretion and the cessation of insulin secretion following 
removal of the stimulus reflects (a) the time for the secreta-
gogue to enter the microcapsule and reach the islet and (b) the 
time for insulin to exit the microcapsule. FIG. 6 depicts a cell 
perfusion system measuring the secretion level of insulin-
releasing islets. Free islets (not encapsulated), islets encap-
sulated in a single-membrane system (encapsulated islets), 
and islets encapsulated in a multi-membrane system (encap-
sulated with layer) were independently assessed. Stimuli for 
insulin secretion are shown in the black bars at the top of the 
graph. Insulin in perfusion fractions collected every 3 min-
utes was quantified by radioimmunoassay. The number of 
islets was not normalized, so the focus of the chart should lie 
on the response time rather than the height of the graphs. The 
similarity of the response time in the three graphs with only 
minute delays suggests that the islets encapsulated in the 
multi-membrane system will function normally inside trans-
planted animals. 
Example 4 
In Vivo Testing of Microcapsules in 
Pancreatectomized Canines 
The biocompatibility and functional capacity of the multi-
membrane encapsulated islets has been studied in a pancre-
atectomized canine model. The animal's size and hence blood 
volume permits the daily evaluations of plasma glucose and 
insulin, clinical assessments of glucose tolerance and evalu-
ations of biocompatibility and safety. In addition, the canine 
model is widely utilized model of human glucose homeosta-
sis and diabetes. Total pancreatectomy in the canine results in 
complete absence of endogenous insulin and thus assess-
ments of insulin concentration can be directly assessed to the 
function and responsiveness of the encapsulated islets. 
20 
Mongrel canines of either sex with a mean wt of 7.6 kg 
were studied. The animals were housed in a facility that met 
the American Association for the Accreditation of Animal 
care guidelines. All animal care procedures were reviewed 
5 and approved by the University of Vanderbilt's Institutional 
Animal Care and Use Committee. Seventeen to twenty four 
days prior to encapsulated islet intraperitoneal administra-
tion, a total pancreatectomy was performed as described 
below. In the post-operative period animals are fed a standard 
io diet of chow and canned diet (34% protein, 14.5% fat, 46% 
carbohydrate, and 5.5% fiber) based on dry weight. Exocrine 
pancreatic enzymes, lipase (70,000 U), amylase (210,000 U) 
and protease (210,000 U) were administered along with their 
meal in order to assist in food digestion and compensate for 
15 the absence of exocrine pancreatic function. Animals 
received daily insulin injections in adjusted dosages to main-
tain euglycemia at 12 hours post feeding without glycosuria 
during 24 hours. The insulin requirements generally range 
from 0.6-0.9 U/kg Regular Pork and 1.0-1.3 U/kg NPH Pork, 
20 q 24 hr. 
After pancreatectomy, daily insulin requirements were 
allowed to stabilize. On the day of encapsulated islet admin-
istration, exogenous insulin is withheld and blood-glucose 
levels were monitored. Animals were fasted 12 hours and 
25 placed under general anesthesia using propofol (4.4 mg.kg , 
IV) and Isoflurane (2.0% with O z, inhalation). A 1.5 cm 
midline laparotomy was performed and a 7.0 mm I.D. can-
nula is inserted into the peritoneal space. A funnel is con-
nected to the free end of the cannula. Encapsulated islets 
30 prepared as described in Example 2 and suspended in modi-
fied Hanks solution containing canine albumin were admin-
istered into the abdominal space at room temperature. Total 
administered packed volume of capsules was 150-200 ml. 
The intraperitoneal cannula was immediately removed and 
35 the laparotomy incision closed. The animal was allowed to 
recover and immediately fed her/his daily ration. The ration 
was consumed within 2 hours from the time of the encapsu-
lated islet administration. Six to eight hours post administra-
tion of food, blood was collected for the assessment of gly- 
40 cemic status and daily collections were performed thereafter 
for 3 days. No immune-suppressive drugs were administered 
to the animals. 
Following the immediate post-administration period, ani-
mals were fed the standard daily rations and blood collections 
45 were performed on 2-3 day intervals for the determination of 
glucose and insulin. At the time of blood collections, animals 
were weighed and general physical conditions were assessed. 
An oral glucose tolerance test was performed at 2-4 weeks 
following encapsulated islet administration. Following an 
50 18-hour fast, an l 8-gauge angiocath was placed into either the 
left or right jugular vein for the collection of blood. Dextrose 
(0.7 gm/kg) was administered orally following the collection 
of a baseline blood sample. Blood samples were collected at 
2.5-minute intervals for the first 20 minutes and 5 and 
55 10-minute intervals thereafter for the 3-hour duration of the 
test. Plasma glucose levels were determined by the glucose 
oxidase method using a Beckman Glucose II analyzer (Beck-
man Instruments Palo Alto Calif.). Plasma insulin was deter-
mined by radioimmunoassay using a double-antibody sys- 
60 tem. 
FIG. 7 depicts the omentum of normal dog shown more 
than six months after treatment (dog received encapsulated 
islets on Feb. 14, 2001 and was sacrificed on Aug. 14, 2001). 
Before sacrifice, no complications were observed in the ani- 
65 mal, and post sacrifice, no abnormalities were observed in or 
on the organs. The figure shows minimal inflammatory 
response and mild vascularization of the omentum. A few 
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capsules (less than 1%), were observed to contain a scant 	 chart, the body weight of the canine remained stable through- 
amount of fibrin and rare mononuclear cells adherent to the 	 out the testing period. FIG. 11 depicts a fructosamine analysis 
surface. The surface of the vast majority of capsules retrieved 	 of canine allotransplantation. The top and bottom panels have 
from the dog were clean and transparent, and barely visible 	 been imported from FIG. 9. The middle panel shows fruc- 
with the naked eye but readily apparent under microscope. 5 tosamine measurements, an indicator of blood glucose level 
Evidence of tissue reactivity has been minimal. There was no 	 averaged over 2-3 weeks in diabetic subjects. A fructosamine 
observed involvement of any other organ system in the 	 level of 400 is roughly equivalent to an Al C measurement of 
splanchnic bed. The capsules loosely adhered to the omentum 	 8.0, which is a similar indicator. The shaded area in the middle 
and were easily washed off, indicating that the capsules were 	 panel shows acceptable fructosamine levels. As can be seen in 
anchored but not imbedded in the omentum. Microcapsule 10 this chart, the fructosamine level on the tested days falls 
integrity was excellent with minimal microcapsule "break- 	 within the acceptable level. The tested fructosamine level is 
age" observed. The retrieved encapsulated islets removed 	 equivalent to anAlClevel ranging from 6.0 (days 110-120) to 
after six and a half months were still alive. 	 8.0 (days 195-200). 
Example 5 	 15 	 Example 6 
In Vivo Testing of Microcapsules in Diabetic 	 Repeated Transplantation of Microcapsules in 
Canines 	 Canines 
Using the total pancreatectomy dog model, the function 20 	 When fasting hyperglycemia recurs in animal, the trans- 
and safety of the intra-peritoneally administered microcap- 	 plant procedure of Example 5 may be repeated to maintain 
sules encapsulating canine islets (allograft) was assessed in 	 normoglycemia. For example, dog 7 received 40,000 EIN/kg, 
10 diabetic animals. Canines were prepared, and microcap- 	 but was only able to maintain some semblance of glucose 
sules implanted, as described in Example 4. The recurrence of 	 control for approximately 90 days. The dog was then given a 
diabetes, as determined by a glucose level of greater than 180 25 second dosage of encapsulated islets of 63,000 EIN/kg total 
mg/dl for 4 consecutive days, occurred in dog 1 at approxi- 	 in two transplants (the transplants were administered a month 
mately 100 days post transplantation. 	 apart due to the availability of the islets). The normoglycemia 
Encapsulated islets were retrieved and tested in the cell 
	
lasted approximately 110 days. These results are similar to 
perfusion system using the same stimuli as described in 	 those observed in the transplantation of dog 6 with 100,000 
Example 3. Results are shown in FIG. 8. The chart in FIG. 8 3o EIN/kg, and of comparable effectiveness in providing fasting 
indicates that the encapsulated islets are still viable as evi- 	 glucose control. 
denced by the response to a high glucose plus IBMX, but have 	 FIG. 12 shows the daily fasting blood glucose of dog 7 at 
reduced insulin secretory capacity. These results suggest that 	 90-110 mg/dl without any supplemental insulin or immuno- 
the diabetes recurred because of inadequate islet mass and 	 suppression. The vertical lines show the day of islet trans- 
further suggest that this is due to reduced islet mass or func-  35 plantation. The top panel shows data points that indicate the 
tion that is not the result of an allograft reaction. 	 venous plasma glucose concentrations collected 12-18 hours 
Fasting glucose concentrations, body weight, and fruc- 	 following a meal. The lower panel indicates the daily dosage 
tosamine measurements of dog 10 are shown in FIGS. 9-11 as 	 of subcutaneous pork insulin administered, with the upper 
representative data. The retrieved capsules were clean and 	 portion of bar indicating NPH insulin, and the lower portion 
intact, suggesting that the longevity of the transplant is no 40 of bar indicating regular insulin. This figure illustrates the 
longer limited by the microcapsule stability, but rather the 	 effectiveness of re-transplantation, as evidenced by the glu- 
loss of islet mass. FIG. 9 depicts blood glucose analysis of 	 cose levels stabilizing immediately after the second trans- 
canine allotransplantation. Transplantation of islets encapsu- 	 plantation. 
lated in a multi-membrane system has demonstrated the effi- 	 These results suggest additional transplants perform just as 
cacy in reversing diabetes in a canine model (dog no. 10) that 45 well if not better than initial transplantation. It is believed that 
has undergone a total pancreatectomy. The top panel illus- 	 the subsequent transplant performs better than the initial 
trates the venous plasma glucose concentrations collected 	 transplant because of the subject's ability to acclimate to the 
12-18 hours following a meal. The lower panel illustrates the 	 treatment and minimize vascularization. Re-transplantation 
daily dosage of subcutaneous porcine insulin administered. 	 provides improved glucose control and was well tolerated in 
The upper portion of bar in the lower panel indicates NPH 50 the animal in terms of biocompatibility. Four successful re- 
insulin and the lower portion of bar indicates regular insulin. 	 transplantations have been performed on one subject; how- 
In days 18 and 19, treatments ceased to verify that the dog was 	 ever, there is no practical limit to the number of re-transplan- 
diabetic. As seen in the top panel, glucose level rose dramati- 	 tations that can be performed on a subject. 
cally when insulin treatments ceased. Insulin treatments 	 Intravenous glucose tolerance test (IVGTT) were per- 
resumed on day 20. On the morning of day 25, insulin treat-  55 formed on all animals to assess the in vivo function of encap- 
ments again ceased. In the afternoon of day 25, islets encap- 	 sulated islets. FIG. 13 illustrates the IVGTT results of dog 5. 
sulated in multi-membrane system were transplanted into the 	 Intravenous dextrose (300 mg/kg) was administered at t=o in 
canine, as indicated by the vertical line. As illustrated in the 	 a canine having previously received a transplantation of islets 
top panel, glucose levels remained stabilized past day 200 at 	 encapsulated in multi-membrane system. Venous samples 
levels comparable or better than those observed during the 60 were collected from the jugular vein to determine plasma 
period of insulin treatment. The bottom panel confirms that 	 glucose and insulin. The subject's blood-glucose level 
no additional insulin treatments were administered during 	 returned to normal at approximately 105 minutes, which is 
this time period. 	 longer, but not unreasonably longer, than the 50-minute aver- 
FIG. 10 depicts body weight analysis of canine allotrans- 	 age exhibited by 6 control dogs. The rate of glucose clearing 
plantation. The top and bottom panels have been imported 65 (the K value) was high, yet within normal range. Circulating 
from FIG. 9. The middle panel shows the animal body weight 	 insulin values for all the transplanted animals increased an 
monitored during the testing period. As can be seen in this 	 average of 40% above basal in 75 minutes of the IVGTT and 
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stayed at that level for the remainder of the test. Dogs with 	 administration was withheld for 36 hours to verify the success 
encapsulated islets did not demonstrate a first-phase insulin 	 of pancreatectomy. On the day of transplantation, general 
release that is often seen in the control animals. The lack of an 	 anesthesia was induced. 3.5-inch midline incisions were per- 
insulin spike in response to glucose challenge (likely due to 	 formed. A total of twelve microcapsule patches containing 
dilution effect of IP transplantation site) may have contrib-  5 300,000 effective human IEQ were administered on top of the 
uted to the islets gradually losing their ability to secrete suf- 	 omentum surface, and then the incision was closed. Upon 
ficient insulin to maintain normoglycemia. 	 anesthetic recovery —15 min, animals were provided their 
daily food ration. No immunosuppressive or anti-inflamma- 
Example 7 	 tory therapies were utilized. One-month in vivo visual inspec- 
10 tion found the microcapsule patches near their original loca- 
Formation of Immunoisolation Patches 	 tions with no visible complications. 
Data presented in Table 1 below indicates that xenotrans- 
Two-membrane microcapsules encapsulating pancreatic 	 plantation was successful, and that there has been continuous 
islets were prepared as described in Examples 2 and 3, and 
	
improvement of glycemic management. For the first three 
mixed thoroughly with biocompatible polymers, such as 15 months, the Lantus® (insulin glargine [rDNA origin] injec- 
sodium alginate (1.5%-3.0%), at a one-to-one ratio. This 	 tion, sold by Sanofi Aventis) requirement was reduced by 
mixture was spread onto a non-wetting surface to form a 	 33%, and average excess blood glucose (BG) level dropped 
circular patch. A circular non-wetting transparent weight was 	 by 33%. Novolin®GE (biosynthetic human insulin, sold by 
placed on top of the polymer patch. Gentle FIG. 8 motion of 
	
Novo Nordisk) requirement remained steady. The last col- 
the weight was used to nudge the capsules into a uniform 20 umn of Table 1 showing the average BG level of 85 more than 
monolayer. With the weight remaining in place, polycation, 	 three months after implantation indicates the ability to sustain 
such as CaC1 21  (1%-1.5%), was introduced to the polymer to 	 blood glucose levels over long periods of time. 
TABLE 1 
Pre-Transplant 
Days 
—33 to —1 0 to 33 
Post-Transplant Days 
34 to 67 	 68 to 101 102 to 135 
Average Plasma Glucose, mg/dl* 182 ± 44 144 ± 36 154 ± 34 137 ± 32 85 ± 20 
Number of Glucose Values a 190 6 5 7 4 0 
Number of Glucose Values s 55 2 0 1 0 1 
Average Daily Novolin ® Adm. 6 6 6 6 6 
Average Daily Lantas ® Adm. 7.4 4.9 5.3 5.1 5.6 
*Mean ± sem 
35 
start the gelling process. As the edge of the patch started to 
show signs of separation from the surface, the weight was 
removed to allow the gelling process to continue. In less than 
10 minutes, the patches were free-floating and ready to be 
washed and transferred for storage in an incubator. Various in 
vitro tests were performed to study the optimal patch param-
eters, and tradeoffs between mass transport and the mechani-
cal strength of patches. Patches of different pore sizes and 
mechanical strength were found to be stable and intact after 
been incubated in a culture medium for 5 weeks at 39 degrees 
C. FIG. 14 is a photograph depicting an immunoisolation 
patch prepared in the described manner. This particular patch 
is circular, approximately 6 cm in diameter, 1 mm in thick-
ness, and contains approximately 6000 microcapsules encap-
sulating approximately 25,000 pancreatic islets. The micro-
capsules are formed in a monolayer. FIG. 15 is a photograph 
demonstrating the ability of an immunoisolation patch to 
remain in place when in a vertical position in a suspension 
dish. 
Example 8 
Canine Immunoisolation Patch Implantation 
Immunoisolation patches comprising microcapsules in a 
biocompatible polymer matrix were formed according to 
Example 7, and implanted in canines. Healthy male mongrel 
canines of —9 kg was utilized as the recipients. The canines 
underwent a total pancreatectomy 28 days prior to transplan-
tation in order to render the animals totally insulin deficient. 
5-7 days prior to islet transplantation, exogenous insulin 
Example 9 
Formation of Immunoisolation Patches & In Vitro 
40 	 Testing 
Alginate-CS beads laden with islets were introduced into 
PLL-PMCG bath for membrane formation. Due to its high 
mobility, PMCG infiltrates Alginate-CS network with ease 
45 and forms the inner membrane layer (-30 µm). On the other 
hand, PLL, due to its low mobility, can only participate with 
PMCG forming a thin PLL-PMCG/Alginate-CS surface 
layer (-30 mu). The inner PMCG/Alginate-CS membrane, 
due to its thickness, plays the key role in mechanical strength 
5o and mass transport functions of the capsules. On the other 
hand, PLL-PMCG/Alginate-CS membrane, due to its uni-
form pore size distribution, plays the key role in immunopro-
tection and due to its more stable chemical bonds, the stabil-
ity. These separations of functions allow more flexibility in 
55 the capsule design. 
The capsules described above were mixed thoroughly with 
biocompatible polymers, such as sodium alginate 
(1.5%-3.0%), at a one-to-one ratio. This mixture was spread 
onto a non-wetting surface to form a circular patch. A circular 
60 non-wetting transparent weight was placed on top of the 
polymer patch. Gentle FIG. 8 motion of the weight was used 
to nudge the capsules into a uniform monolayer. With the 
weight remaining in place, polycation, such as CaC1 21  (1%-
1.5%), was introduced to the polymer to start the gelling 
65 process. As the edge of the patch started to show signs of 
separation from the surface, the weight was removed to allow 
the gelling process to continue. In less than 10 minutes, the 
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patches were free-floating and ready to be washed and trans-
ferred for storage in an incubator. 
An in vitro study was performed to test the stability of the 
capsule-patch (CP) of different functional parameters and 
dimensions. Aside from overcoming gravitational sedimen-
tation, lab study has shown planar geometry of CP tolerates 
better the capsule volume expansion and contraction cycle. 
Capsules with larger pores (lower polymer density) that col-
lapse in spherical geometry can now be considered, thus, a 
greater degree of freedom in capsule design. CP of different 
pore sizes and mechanical strength were found to be stable 
and intact after being incubated in different culture mediums 
for 5 weeks at 39° C. 
Example 10 
Additional Studies in Canines 
Capsules and immunoisolation patches were formed 
according to Example 9. A study was performed to test the 
effectiveness of the immunoisolation patches in the subcuta-
neous space in order to enhance a stratified engraftment of 
26 
enous insulin, which was measured as the circulating plasma 
insulin concentration (fasting) assessed at the same time that 
the daily glucose measurements were performed. 
A study was also performed to test the ability of the immu- 
5 noisolation patch (capsule-patch) to anchor encapsulated 
islets on the omental surface, and its effectiveness in provid-
ing xenoprotection of human islets in the canine model. 
Totally pancreatectomized male mongrel canines of —9 kg 
were utilized as the recipients. Capsule-patches containing 
10 less than one-third of the needed dosage of human IEQ for 
insulin independence were administered on top of the omen-
tal surface. No immuno suppressive or anti-inflammatory 
therapies were utilized. One-month in vivo visual inspection 
found the capsule-patches (CP) near their original locations 
15 with no visible complications. Post-mortem examination (>5 
months) showed that almost all the capsules stayed on the 
omental surface. The majority of them were intact with viable 
islets. The transplantation of sub-dosage encapsulated islets 
offered therapeutic benefits as seen in Table 2. This experi- 
20 ment demonstrated the effectiveness of CP overcoming the 
gravitational sedimentation problem as well as providing 
excellent immunoprotection. 
TABLE 2 
Pre-Transplant 
Days 	 Post-Transplant Days 
—33 to —1 	 0 to 33 	 34 to 67 	 68 to 101 102 to 120 
Average Plasma Glucose, mg/dl* 	 182 ± 44 	 144 ± 36 154 ± 34 137 ± 32 	 81 ± 25 
Number of Glucose values a 190 	 6 	 5 	 7 	 4 	 0 
Number of Glucose values s 55 	 2 	 0 	 1 	 0 	 1 
Average Daily Lantas ® Adm. 	 7.4 	 4.9 	 5.3 	 5.1 	 5.6 
*Mean ± sem 
encapsulated islets to maximize the encapsulated islet envi-
ronment. A pancreatectomized canine weighing —6 kg was 
utilized as the recipient. A capsule-patch containing 25,000 
canine IEQ was transplanted into the subcutaneous space on 
the side of the animal. Postmortem examination at five 
months revealed encapsulated islets were in the original loca-
tion and embedded into the subcutaneous layer. The capsules 
were visibly intact with some neovascularization on the dor-
sal surface of the embedded encapsulated islets, as depicted in 
FIG. 18 (depicting a capsule-patch retrieved from canine 
number 626). 
In another study, the capsules were transplanted into nine 
totally pancreatectomized dogs, and normalized fasting 
blood glucose levels in nine out of nine dogs for up to two-
hundred and fourteen days with a single transplantation. Fast-
ing glucose concentrations, body weight, plasma fruc-
tosamine measurements and insulin levels (exogenous and 
endogenous) of canine number 141 are shown in FIG. 19 as 
representative data. Re-transplantation was assessed in three 
animals, and encapsulated islets were effective in providing 
fasting glycolic control after the initial transplantation had 
run its course. No immunosuppressant or anti-inflammatory 
therapy was utilized. 
In FIG. 19, the upper panel indicates venous plasma glu-
cose concentrations collected 6-18 hours following a meal, 
the second panel from the top indicates the recipient's body 
weight in kilograms, the third panel from the top indicates 
venous plasma fructosamine concentrations, and the bottom 
panel indicates insulin levels. Insulin levels include levels of 
exogenous insulin (NPH or regular pork insulin), which was 
administered daily up until the time of islet administration, 
and then again after 214 days, and levels of circulating endog- 
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The above description, drawings and examples are only 
illustrative of preferred embodiments which achieve the 
objects, features and advantages of the present invention. It is 
not intended that the present invention be limited to the illus- 
40 trative embodiments. Any modification of the present inven-
tion which comes within the spirit and scope of the following 
claims should be considered part of the present invention. 
What is claimed is: 
1. An immunoisolation patch for use in cellular transplan-
45 tation therapy of a disorder, comprising: 
• plurality of multi-membrane microcapsules which 
encapsulate cellular material; and 
• biocompatible support matrix in which the plurality of 
multi-membrane microcapsules are distributed; 
50 wherein at least some of said plurality of multi-membrane 
microcapsules comprise at least two membrane layers: 
an inner membrane biocompatible with the encapsu- 
lated cellular material, the inner membrane compris- 
ing sodium alginate, cellulose sulfate, and a multi- 
55 	 component polycation; and 
an outer membrane which provides chemical stability to 
the immunoisolation patch and which bonds the 
microcapsule to the support matrix, the outer mem-
brane comprising a polyion and at least one com- 
60 pound selected from the group consisting of sodium 
alginate, cellulose sulfate, and poly(methylene-co-
guanidine); and 
whereinthe supportmatrix comprises a carbohydrate poly-
mer having carboxylate or sulfate groups, and an inor-
65 	 ganic salt. 
2. The immunoisolation patch of claim 1, wherein the 
disorder is an endocrine disorder. 
US 8,673,294 B2 
27 
3. The immunoisolation patch of claim 2, wherein the 
endocrine disorder is diabetes and the cellular material is 
pancreatic beta cells, pancreatic islets, or other insulin-pro-
ducing islets, or a combination thereof. 
4. The immunoisolation patch of claim 2, wherein the 
endocrine disorder is hypothyroidism and the cellular mate-
rial comprises one or more of thyroid follicular cells, parafol-
licular cells, or thyroid follicles. 
5. The immunoisolation patch of claim 1, wherein the 
disorder is a neurological disorder. 
6. An immunoisolation patch for use in cellular transplan- 
tation therapy for a pancreatic disorder, comprising: 
a plurality of multi-membrane microcapsules which 
encapsulate pancreatic cellular material; and 
a biocompatible support matrix in which the plurality of 
multi-membrane microcapsules are distributed; 
wherein at least some of said plurality of multi-membrane 
microcapsules comprise at least two membrane layers: 
an inner membrane biocompatible with the encapsu- 
lated cellular material, the inner membrane compris- 
ing sodium alginate, cellulose sulfate, and a multi- 
component polycation; and 
an outer membrane which provides chemical stability to 
the immunoisolation patch and which bonds the 
microcapsule to the support matrix, the outer mem-
brane comprising a polyion and at least one com-
pound selected from the group consisting of sodium 
alginate, cellulose sulfate, and poly(methylene-co-
guanidine); and 
wherein the supportmatrix comprises a carbohydrate poly-
mer having carboxylate or sulfate groups, and an inor-
ganic salt. 
7. The immunoisolation patch of claim 6, wherein the 
pancreatic disorder is diabetes and the pancreatic cellular 
material is pancreatic beta cells, pancreatic islets, or other 
insulin-producing islets, or a combination thereof. 
8. The immunoisolation patch of claim 7, wherein the 
pancreatic cellular material is pancreatic islets. 
9. The immunoisolation patch of claim 1, wherein: 
the inner membrane is about 5 to about 100 microns thick, 
and the outer membrane is less than about 5 microns 
thick, and 
the multi-membrane microcapsule has a porosity cutoff of 
about 50 to about 250 kilodaltons. 
10. The immunoisolation patch of claim 1, wherein the 
multi-component polycation of the inner membrane com-
prises polymethylene-co-guanidine and one or both of cal-
cium chloride and sodium chloride and wherein the polyion 
of the outer membrane is selected from the group consisting 
of poly-L-lysine, poly-D-lysine, poly-L,D-lysine, poly-L-or-
nithine, poly-D-ornithine, poly-L,D-ornithine, chitosan, 
polyacrylamide, poly(vinyl alcohol), and combinations 
thereof. 
11. The immunoisolation patch of claim 1, wherein the 
inner membrane comprises calcium chloride, cellulose sul-
fate, polymethylene-co-guanidine and sodium alginate, the 
outer membrane comprises cellulose sulfate, poly-L-lysine, 
polymethylene-co-guanidine, and sodium alginate, and the 
support matrix comprises calcium chloride and sodium algi-
nate. 
12. The immunoisolation patch of claim 1, wherein each of 
the membranes comprises at least one compound selected 
from the group consisting of calcium chloride, cellulose sul-
fate, poly-L-lysine, polymethylene-co-guanidine and sodium 
alginate and wherein the plurality of multi-membrane micro-
capsules are distributed in the support matrix as a monolayer. 
28 
13. A method of cellular transplantation therapy of a dis-
order, comprising: 
administering to a mammalian subject in need thereof an 
immunoisolation patch, wherein the immunoisolation 
5 	 patch comprises: 
a plurality of multi-membrane microcapsules which 
encapsulate cellular material; and 
a biocompatible support matrix in which the plurality of 
multi-membrane microcapsules are distributed, 
l0 
wherein at least some of said plurality of multi-membrane 
microcapsules comprise at least two membrane layers: 
an inner membrane biocompatible with the encapsu- 
lated cellular material, the inner membrane compris- 
15 	 ing sodium alginate, cellulose sulfate, and a multi- 
component polycation; and 
an outer membrane which provides chemical stability to 
the immunoisolation patch and which bonds the 
microcapsule to the support matrix, the outer mem- 
20 bran comprising a polyion and at least one com-
pound selected from the group consisting of sodium 
alginate, cellulose sulfate, and poly(methylene-co-
guanidine), and 
whereinthe supportmatrix comprises a carbohydrate poly-
25 	 mer having carboxylate or sulfate groups, and an inor- 
ganic salt. 
14. The method of claim 13, wherein the disorder is 
selected from diabetes, hypothyroidism, and a neurological 
disorder. 
30 	 15. The method of claim 13, wherein: 
the inner membrane is about 5 to about 100 microns thick 
and the outer membrane is less than about 5 microns 
thick, and 
the multi-membrane microcapsule has a porosity cutoff of 
35 	 about 50 to about 250 kilodaltons. 
16. The method of claim 13, wherein: 
the multi-component polycation of the inner membrane 
comprises polymethylene-co-guanidine and one or both 
of calcium chloride and sodium chloride, and the poly- 
40 ion of the outer membrane is selected from the group 
consisting of poly-L-lysine, poly-D-lysine, poly-L,D-
lysine, poly-L-omithine, poly-D-ornithine, poly-L,D-
ornithine, chitosan, polyacrylamide, poly(vinyl alco-
hol), and combinations thereof. 
45 	 17. The method of claim 13, wherein: 
the inner membrane comprises calcium chloride, cellulose 
sulfate, polymethylene-co-guanidine and sodium algi-
nate, 
the outer membrane comprises cellulose sulfate, poly-L-
50 	 lysine, polymethylene-co-guanidine, and sodium algi- 
nate, and 
the support matrix comprises calcium chloride and sodium 
alginate. 
18. The method of claim 13, wherein each of the mem- 
55 brans and the support matrix comprises at least one com-
pound selected from the group consisting of calcium chloride, 
cellulose sulfate, poly-L-lysine, polymethylene-co-guani-
dine and sodium alginate and the plurality of multi-mem-
brane microcapsules are distributed in the support matrix as a 
60 monolayer. 
19. A method of cellular transplantation therapy of a pan-
creatic disorder, comprising: 
administering to a mammalian subject in need thereof an 
immunoisolation patch, wherein the immunoisolation 
65 	 patch comprises: 
a plurality of multi-membrane microcapsules which 
encapsulate pancreatic cellular material; and 
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a biocompatible support matrix in which the plurality of 
multi-membrane microcapsules are distributed, 
wherein at least some of said plurality of multi-membrane 
microcapsules comprise at least two membrane layers: 
an inner membrane biocompatible with the encapsu- 
lated cellular material, the inner membrane compris- 
ing sodium alginate, cellulose sulfate, and a multi- 
component polycation; and 
an outer membrane which provides chemical stability to 
the immunoisolation patch and which bonds the 
microcapsule to the support matrix, the outer mem-
brane comprising a polyion and at least one com-
pound selected from the group consisting of sodium 
alginate, cellulose sulfate, and poly(methylene-co-
guanidine), and 
wherein the supportmatrix comprises a carbohydrate poly-
mer having carboxylate or sulfate groups, and an inor-
ganic salt. 
20. The method of claim 19, wherein the pancreatic disor-
der is diabetes and the pancreatic cellular material is pancre-
atic beta cells, pancreatic islets, or other insulin-producing 
islets, or a combination thereof. 
21. A method of stabilizing the glucose level in a mamma-
lian subject for at least 30 days, comprising: 
administering to a mammalian subject in need thereof an 
immunoisolation patch, wherein the immunoisolation 
patch comprises: 
30 
a plurality of multi-membrane microcapsules which 
encapsulate pancreatic cellular material; and 
a biocompatible support matrix in which the plurality of 
multi-membrane microcapsules are distributed, 
5 wherein at least some of said plurality of multi-membrane 
microcapsules comprise at least two membrane layers: 
an inner membrane biocompatible with the encapsu- 
lated cellular material, the inner membrane compris- 
ing sodium alginate, cellulose sulfate, and a multi- 
component polycation; and 
an outer membrane which provides chemical stability to 
the immunoisolation patch and which bonds the 
microcapsule to the support matrix, the outer mem-
brane comprising a polyion and at least one com- 
as pound selected from the group consisting of sodium 
alginate, cellulose sulfate, and poly(methylene-co-
guanidine), and 
whereinthe supportmatrix comprises a carbohydrate poly- 
20 
mer having carboxylate or sulfate groups, and an inor-
ganic salt; 
wherein said administration results in a stabilization of the 
glucose level in the mammalian subject for at least 30 
days. 
25 	
22. The method of claim 21, wherein the subject is a 
human. 
